慢性阻塞性肺疾病合并肌少癥性肥胖的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

張佳麗 ^1,2 ,  胡福英 ^1,2

1. ;
2. ;

Corresponding?author：

胡福英, Email: 150611780@qq.com

Keywords：

DOI：

10.7507/1671-6205.202601054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張佳麗, 胡福英. 慢性阻塞性肺疾病合并肌少癥性肥胖的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2026, 25(8): 607-612. doi: 10.7507/1671-6205.202601054 Copy

1.	Global initiative for chronic obstructive lung disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report[EB/OL]. (2025). [ 2025-12-21]. https://goldcopd.org/2026-gold-report/.
2.	劉敏, 侯天強, 姜黔峰. 肌少癥指數與慢性阻塞性肺疾病嚴重程度的相關性研究[J]. 中國呼吸與危重監護雜志, 2025, 24(9): 653-660.
3.	Chen LK, Hsiao FY, Akishita M, et al. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update[J]. Nat Aging, 2025, 5(11): 2164-2175.
4.	Zhu J, Zhao Z, Wu B, et al. Effect of Body Mass Index on Lung Function in Chinese Patients with Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2477-2486.
5.	Baumgartner RN, Body composition in healthy aging[J]. Ann N Y Acad Sci, 2000, 904: 437-448.
6.	翟興月, 韓云琰, 周蕓. 肌少癥性肥胖的發病機制及診療研究進展, 腫瘤代謝與營養電子雜志[J]. 2023, 10(5): 579-584.
7.	王煜旻, 殷少軍, 張煜, 等. 上海郊區慢性阻塞性肺疾病患者肌少性肥胖的發生率及其對失能風險的影響[J]. 海南醫學, 2026, 37(1): 20-24.
8.	Wang Z, Zhou X, Deng M, et al. Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study[J]. BMC Pulm Med, 2023, 23(1): 394.
9.	Limpawattana P, Inthasuwan P, Putraveephong S, et al. Sarcopenia in chronic obstructive pulmonary disease: A study of prevalence and associated factors in the Southeast Asian population[J]. Chron Respir Dis, 2018, 15(3): 250-257.
10.	Koo HK, Park JH, Park HK, et al. Conflicting role of sarcopenia and obesity in male patients with chronic obstructive pulmonary disease: Korean National Health and Nutrition Examination Survey[J]. PLoS One, 2014, 9(10): e110448.
11.	Yang J, Wang Y, Shi X, et al. Prevalence of sarcopenic obesity among older adults in communities of China: A multicenter, cross-sectional study[J]. Nutr Clin Pract, 2024 Dec, 39(6): 1375-1387.
12.	Nagano A, Wakabayashi H, Maeda K, et al. Respiratory Sarcopenia and Sarcopenic Respiratory Disability: Concepts, Diagnosis, and Treatment[J]. J Nutr Health Aging, 2021, 25(4): 507-515.
13.	Cao Y, Li P, Wang Y, et al. Diaphragm Dysfunction and Rehabilitation Strategy in Patients With Chronic Obstructive Pulmonary Disease[J]. Front Physiol, 2022 May 2, 13: 872277.
14.	Melo LC, Silva MA, Calles AC, Obesity and lung function: a systematic review[J]. Einstein (Sao Paulo), 2014, 12(1): 120-125.
15.	Cuttitta G, Ferraro M, Cibella F, et al. Relationship among Body Composition, Adipocytokines, and Irisin on Exercise Capacity and Quality of Life in COPD: A Pilot Study[J]. Biomolecules, 2022, 13(1): 48.
16.	Jiang Q, Ma Z, Sun J, et al. Association of dietary inflammatory indices with sarcopenia and all-cause mortality in COPD patients[J]. Front Nutr, 2024, 11: 1395170.
17.	Leem AY, Kim YS, Chung KS, et al. Sarcopenia is associated with cardiovascular risk in men with COPD, independent of adiposity[J]. Respir Res, 2022, 23(1): 185.
18.	Henrot P, Dupin I, Schilfarth P, et al. Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting[J]. Int J Mol Sci, 2023, 24(7): 6454.
19.	Zhao J, Zeng L, Liang G, et al. Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18-59 years: a population-based study[J]. Sci Rep, 2023, 13(1): 22156.
20.	Borba VZC, Costa TMDRL, Sarcopenic obesity: a review. Arch Endocrinol Metab[J]. 2025, 68: e240084.
21.	Gao J, Deng M, Li Y, et al. Resistin as a Systemic Inflammation-Related Biomarker for Sarcopenia in Patients With Chronic Obstructive Pulmonary Disease[J] Front Nutr, 2022, 9: 921399.
22.	Yang ZY, Chen WL, Examining the Association Between Serum Leptin and Sarcopenic Obesity[J]. J Inflamm Res, 2021, 14: 3481-3487.
23.	Albano GD, Gagliardo RP, Montalbano AM, et al. Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases[J]. Antioxidants (Basel), 2022, 11(11): 2237.
24.	Fan R, Hao Y, Du Q, et al. Beneficial Effects of Walnut Oligopeptides on Muscle Loss in Senescence-Accelerated Mouse Prone-8 (SAMP8) Mice: Focusing on Mitochondrial Function[J]. Nutrients, 2022, 14(10): 2051.
25.	Gonzalez A, Simon F, Achiardi O, et al. The Critical Role of Oxidative Stress in Sarcopenic Obesity[J]. Oxid Med Cell Longev, 2021, 2021: 4493817.
26.	Saso L, Ates I, Tunc R, et al. Modulation of Nrf2 and Mitochondrial Function: Pharmacological Implications[J]. Pharmaceuticals (Basel), 2025, 18(11): 1698.
27.	Saha S, Buttari B, Panieri E, et al. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation[J]. Molecules, 2020, 25(22): 5474.
28.	Liu Y, Teo SM, Méric G, et al. The gut microbiome is a significant risk factor for future chronic lung disease[J]. J Allergy Clin Immunol, 2023, 151(4): 943-952.
29.	Wang L, Cai Y, Garssen J, et al. The Bidirectional Gut-Lung Axis in Chronic Obstructive Pulmonary Disease[J]. Am J Respir Crit Care Med, 2023, 207(9): 1145-1160.
30.	He Y, Wen Q, Yao F, et al. Gut-lung axis: The microbial contributions and clinical implications[J]. Crit Rev Microbiol, 2017, 43(1): 81-95.
31.	宋承雅, 楊穎, 洪侃. 短鏈脂肪酸對老年2型糖尿病合并肌少癥的影響及其機制[J]. 實用老年醫學, 2025, 39(1): 98-101+108.
32.	Anachad O, Taouil A, Taha W, et al. The Implication of Short-Chain Fatty Acids in Obesity and Diabetes. Microbiol Insights, 2023, 16: 11786361231162720.
33.	Yu W, Lan Y, Sun D, et al. Prevalence and Risk Factors for Chronic Obstructive Pulmonary Disease Among Adults Aged 50 and Above-10 CKB Study Areas, China, 2020-2021[J]. China CDC Wkly, 2024, 6(43): 1126-1131.
34.	Tan Y, Ye Y, Huang C, et al. Cigarette Smoking Induces Skeletal Muscle Atrophy in Mice by Activated Macrophage-Mediated Pyroptosis[J]. J Inflamm Res, 2025, 18: 2447-2464.
35.	Lippi L, Folli A, Curci C, et al. Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?[J]. Int J Environ Res Public Health, 2022, 19(21): 14314.
36.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組, 中國醫師協會呼吸醫師分會慢性阻塞性肺疾病工作委員會, 慢性阻塞性肺疾病診治指南(2021年修訂版)[J]. 中華結核和呼吸雜志, 2021, 44(03): 170-205.
37.	中華人民共和國國家衛生健康委員會醫政司, 肥胖癥診療指南(2024年版)[J]. 中華消化外科雜志, 2024, 23(10): 1237-1260.
38.	中華人民共和國國家衛生健康委員會, 中國臨床戒煙指南(2015年版)[J]. 臨床指南匯編數據庫, 2019, 1(1): e52-e70.
39.	Wang H, Huang WY, Zhao Y. Efficacy of Exercise on Muscle Function and Physical Performance in Older Adults with Sarcopenia: An Updated Systematic Review and Meta-Analysis[J]. Int J Environ Res Public Health, 2022, 19(13): 8212.
40.	Chen N, He X, Feng Y, et al. Effects of resistance training in healthy older people with sarcopenia: a systematic review and meta-analysis of randomized controlled trials[J]. Eur Rev Aging Phys Act, 2021, 18(1): 23.
41.	Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies[J]. Nat Rev Endocrinol, 2018, 14(9): 513-537.
42.	中國營養學會肥胖防控分會, 中國營養學會臨床營養分會, 中華預防醫學會行為健康分會, 等, 中國居民肥胖防治專家共識[J]. 中國預防醫學雜志, 2022, 23(5): 321-339.
43.	Xu ZR, Tan ZJ, Zhang Q, et al. The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis[J]. Br J Nutr, 2015, 113(1): 25-34.
44.	Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis[J]. J Gastroenterol, 2018, 53(3): 427-437.
45.	Yang W, Lee JW, Kim Y, et al. Increased Omega-3 Fatty Acid Intake is Inversely Associated with Sarcopenic Obesity in Women but not in Men, Based on the 2014-2018 Korean National Health and Nutrition Examination Survey[J]. J Clin Med, 2020, 9(12): 3856.
46.	Dzik KP, Kaczor JJ. Mechanisms of vitamin D on skeletal muscle function: oxidative stress, energy metabolism and anabolic state[J]. Eur J Appl Physiol, 2019, 119(4): 825-839.
47.	劉俊麟, 劉祁祁, 李星, 等. 生物制劑靶向治療慢性阻塞性肺疾病的研發進展[J]. 中國呼吸與危重監護雜志, 2025, 24(8): 601-608.
48.	Xiong Y, Hu JQ, Tang HL, et al. Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease, Front Med (Lausanne)[J]. 2024, 11: 1334442.
49.	Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study[J]. Lancet Respir Med, 2014, 2(11): 891-901.
50.	Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1755-1770.
51.	Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study[J]. Lancet, 2002, 359(9310): 926-930.
52.	Ata AM, Kara M, Ekiz T, et al. Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel[J]. Int J Clin Pract, 2021, 75(3): e13800.
53.	Springer J, von Haehling S. ACE Inhibitors and Sarcopenia: Covering All the BASEs?[J]. Drugs Aging, 2016, 33(11): 839-840.
54.	袁瑾, 方玲娜, 李翀. SARMs在肌少癥治療中的機制與進展[J]. 中國骨質疏松雜志, 2024, 30(5): 775-780.
55.	Mastaitis JW, Gomez D, Raya JG, et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates[J]. Nat Commun, 2025, 16(1): 4377.
56.	Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 402(10403): 705-719.
57.	Christensen MB, Gasbjerg LS, Heimbürger SM, et al. GIP's involvement in the pathophysiology of type 2 diabetes[J]. Peptides, 2020, 125: 170178.
58.	Tan TM, Minnion J, Khoo B, et al. Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial[J]. Diabetes Obes Metab, 2021, 23(7): 1471-1483.
59.	Venniyoor A. Tirzepatide Once Weekly for the Treatment of Obesity[J]. N Engl J Med, 2022, 387(15): 1433-1434.
60.	Hope DCD, Hinds CE, Lopes T, et al. Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss[J]. Cell Rep Med, 2022, 3(11): 100810.
61.	Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept[J]. Cell Metab, 2022, 34(9): 1234-1247. e9.
62.	Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial[J]. JAMA Netw Open, 2021, 4(1): e2033457.
63.	Deaton AM, Dubey A, Ward LD, et al. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity[J]. Nat Commun, 2022, 13(1): 4319.
64.	Akbari P, Sosina OA, Bovijn J, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes[J]. Nat Commun, 2022, 13(1): 4844.

1. Global initiative for chronic obstructive lung disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report[EB/OL]. (2025). [ 2025-12-21]. https://goldcopd.org/2026-gold-report/.
2. 劉敏, 侯天強, 姜黔峰. 肌少癥指數與慢性阻塞性肺疾病嚴重程度的相關性研究[J]. 中國呼吸與危重監護雜志, 2025, 24(9): 653-660.
3. Chen LK, Hsiao FY, Akishita M, et al. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update[J]. Nat Aging, 2025, 5(11): 2164-2175.
4. Zhu J, Zhao Z, Wu B, et al. Effect of Body Mass Index on Lung Function in Chinese Patients with Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2477-2486.
5. Baumgartner RN, Body composition in healthy aging[J]. Ann N Y Acad Sci, 2000, 904: 437-448.
6. 翟興月, 韓云琰, 周蕓. 肌少癥性肥胖的發病機制及診療研究進展, 腫瘤代謝與營養電子雜志[J]. 2023, 10(5): 579-584.
7. 王煜旻, 殷少軍, 張煜, 等. 上海郊區慢性阻塞性肺疾病患者肌少性肥胖的發生率及其對失能風險的影響[J]. 海南醫學, 2026, 37(1): 20-24.
8. Wang Z, Zhou X, Deng M, et al. Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study[J]. BMC Pulm Med, 2023, 23(1): 394.
9. Limpawattana P, Inthasuwan P, Putraveephong S, et al. Sarcopenia in chronic obstructive pulmonary disease: A study of prevalence and associated factors in the Southeast Asian population[J]. Chron Respir Dis, 2018, 15(3): 250-257.
10. Koo HK, Park JH, Park HK, et al. Conflicting role of sarcopenia and obesity in male patients with chronic obstructive pulmonary disease: Korean National Health and Nutrition Examination Survey[J]. PLoS One, 2014, 9(10): e110448.
11. Yang J, Wang Y, Shi X, et al. Prevalence of sarcopenic obesity among older adults in communities of China: A multicenter, cross-sectional study[J]. Nutr Clin Pract, 2024 Dec, 39(6): 1375-1387.
12. Nagano A, Wakabayashi H, Maeda K, et al. Respiratory Sarcopenia and Sarcopenic Respiratory Disability: Concepts, Diagnosis, and Treatment[J]. J Nutr Health Aging, 2021, 25(4): 507-515.
13. Cao Y, Li P, Wang Y, et al. Diaphragm Dysfunction and Rehabilitation Strategy in Patients With Chronic Obstructive Pulmonary Disease[J]. Front Physiol, 2022 May 2, 13: 872277.
14. Melo LC, Silva MA, Calles AC, Obesity and lung function: a systematic review[J]. Einstein (Sao Paulo), 2014, 12(1): 120-125.
15. Cuttitta G, Ferraro M, Cibella F, et al. Relationship among Body Composition, Adipocytokines, and Irisin on Exercise Capacity and Quality of Life in COPD: A Pilot Study[J]. Biomolecules, 2022, 13(1): 48.
16. Jiang Q, Ma Z, Sun J, et al. Association of dietary inflammatory indices with sarcopenia and all-cause mortality in COPD patients[J]. Front Nutr, 2024, 11: 1395170.
17. Leem AY, Kim YS, Chung KS, et al. Sarcopenia is associated with cardiovascular risk in men with COPD, independent of adiposity[J]. Respir Res, 2022, 23(1): 185.
18. Henrot P, Dupin I, Schilfarth P, et al. Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting[J]. Int J Mol Sci, 2023, 24(7): 6454.
19. Zhao J, Zeng L, Liang G, et al. Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18-59 years: a population-based study[J]. Sci Rep, 2023, 13(1): 22156.
20. Borba VZC, Costa TMDRL, Sarcopenic obesity: a review. Arch Endocrinol Metab[J]. 2025, 68: e240084.
21. Gao J, Deng M, Li Y, et al. Resistin as a Systemic Inflammation-Related Biomarker for Sarcopenia in Patients With Chronic Obstructive Pulmonary Disease[J] Front Nutr, 2022, 9: 921399.
22. Yang ZY, Chen WL, Examining the Association Between Serum Leptin and Sarcopenic Obesity[J]. J Inflamm Res, 2021, 14: 3481-3487.
23. Albano GD, Gagliardo RP, Montalbano AM, et al. Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases[J]. Antioxidants (Basel), 2022, 11(11): 2237.
24. Fan R, Hao Y, Du Q, et al. Beneficial Effects of Walnut Oligopeptides on Muscle Loss in Senescence-Accelerated Mouse Prone-8 (SAMP8) Mice: Focusing on Mitochondrial Function[J]. Nutrients, 2022, 14(10): 2051.
25. Gonzalez A, Simon F, Achiardi O, et al. The Critical Role of Oxidative Stress in Sarcopenic Obesity[J]. Oxid Med Cell Longev, 2021, 2021: 4493817.
26. Saso L, Ates I, Tunc R, et al. Modulation of Nrf2 and Mitochondrial Function: Pharmacological Implications[J]. Pharmaceuticals (Basel), 2025, 18(11): 1698.
27. Saha S, Buttari B, Panieri E, et al. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation[J]. Molecules, 2020, 25(22): 5474.
28. Liu Y, Teo SM, Méric G, et al. The gut microbiome is a significant risk factor for future chronic lung disease[J]. J Allergy Clin Immunol, 2023, 151(4): 943-952.
29. Wang L, Cai Y, Garssen J, et al. The Bidirectional Gut-Lung Axis in Chronic Obstructive Pulmonary Disease[J]. Am J Respir Crit Care Med, 2023, 207(9): 1145-1160.
30. He Y, Wen Q, Yao F, et al. Gut-lung axis: The microbial contributions and clinical implications[J]. Crit Rev Microbiol, 2017, 43(1): 81-95.
31. 宋承雅, 楊穎, 洪侃. 短鏈脂肪酸對老年2型糖尿病合并肌少癥的影響及其機制[J]. 實用老年醫學, 2025, 39(1): 98-101+108.
32. Anachad O, Taouil A, Taha W, et al. The Implication of Short-Chain Fatty Acids in Obesity and Diabetes. Microbiol Insights, 2023, 16: 11786361231162720.
33. Yu W, Lan Y, Sun D, et al. Prevalence and Risk Factors for Chronic Obstructive Pulmonary Disease Among Adults Aged 50 and Above-10 CKB Study Areas, China, 2020-2021[J]. China CDC Wkly, 2024, 6(43): 1126-1131.
34. Tan Y, Ye Y, Huang C, et al. Cigarette Smoking Induces Skeletal Muscle Atrophy in Mice by Activated Macrophage-Mediated Pyroptosis[J]. J Inflamm Res, 2025, 18: 2447-2464.
35. Lippi L, Folli A, Curci C, et al. Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?[J]. Int J Environ Res Public Health, 2022, 19(21): 14314.
36. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組, 中國醫師協會呼吸醫師分會慢性阻塞性肺疾病工作委員會, 慢性阻塞性肺疾病診治指南(2021年修訂版)[J]. 中華結核和呼吸雜志, 2021, 44(03): 170-205.
37. 中華人民共和國國家衛生健康委員會醫政司, 肥胖癥診療指南(2024年版)[J]. 中華消化外科雜志, 2024, 23(10): 1237-1260.
38. 中華人民共和國國家衛生健康委員會, 中國臨床戒煙指南(2015年版)[J]. 臨床指南匯編數據庫, 2019, 1(1): e52-e70.
39. Wang H, Huang WY, Zhao Y. Efficacy of Exercise on Muscle Function and Physical Performance in Older Adults with Sarcopenia: An Updated Systematic Review and Meta-Analysis[J]. Int J Environ Res Public Health, 2022, 19(13): 8212.
40. Chen N, He X, Feng Y, et al. Effects of resistance training in healthy older people with sarcopenia: a systematic review and meta-analysis of randomized controlled trials[J]. Eur Rev Aging Phys Act, 2021, 18(1): 23.
41. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies[J]. Nat Rev Endocrinol, 2018, 14(9): 513-537.
42. 中國營養學會肥胖防控分會, 中國營養學會臨床營養分會, 中華預防醫學會行為健康分會, 等, 中國居民肥胖防治專家共識[J]. 中國預防醫學雜志, 2022, 23(5): 321-339.
43. Xu ZR, Tan ZJ, Zhang Q, et al. The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis[J]. Br J Nutr, 2015, 113(1): 25-34.
44. Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis[J]. J Gastroenterol, 2018, 53(3): 427-437.
45. Yang W, Lee JW, Kim Y, et al. Increased Omega-3 Fatty Acid Intake is Inversely Associated with Sarcopenic Obesity in Women but not in Men, Based on the 2014-2018 Korean National Health and Nutrition Examination Survey[J]. J Clin Med, 2020, 9(12): 3856.
46. Dzik KP, Kaczor JJ. Mechanisms of vitamin D on skeletal muscle function: oxidative stress, energy metabolism and anabolic state[J]. Eur J Appl Physiol, 2019, 119(4): 825-839.
47. 劉俊麟, 劉祁祁, 李星, 等. 生物制劑靶向治療慢性阻塞性肺疾病的研發進展[J]. 中國呼吸與危重監護雜志, 2025, 24(8): 601-608.
48. Xiong Y, Hu JQ, Tang HL, et al. Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease, Front Med (Lausanne)[J]. 2024, 11: 1334442.
49. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study[J]. Lancet Respir Med, 2014, 2(11): 891-901.
50. Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1755-1770.
51. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study[J]. Lancet, 2002, 359(9310): 926-930.
52. Ata AM, Kara M, Ekiz T, et al. Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel[J]. Int J Clin Pract, 2021, 75(3): e13800.
53. Springer J, von Haehling S. ACE Inhibitors and Sarcopenia: Covering All the BASEs?[J]. Drugs Aging, 2016, 33(11): 839-840.
54. 袁瑾, 方玲娜, 李翀. SARMs在肌少癥治療中的機制與進展[J]. 中國骨質疏松雜志, 2024, 30(5): 775-780.
55. Mastaitis JW, Gomez D, Raya JG, et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates[J]. Nat Commun, 2025, 16(1): 4377.
56. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 402(10403): 705-719.
57. Christensen MB, Gasbjerg LS, Heimbürger SM, et al. GIP's involvement in the pathophysiology of type 2 diabetes[J]. Peptides, 2020, 125: 170178.
58. Tan TM, Minnion J, Khoo B, et al. Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial[J]. Diabetes Obes Metab, 2021, 23(7): 1471-1483.
59. Venniyoor A. Tirzepatide Once Weekly for the Treatment of Obesity[J]. N Engl J Med, 2022, 387(15): 1433-1434.
60. Hope DCD, Hinds CE, Lopes T, et al. Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss[J]. Cell Rep Med, 2022, 3(11): 100810.
61. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept[J]. Cell Metab, 2022, 34(9): 1234-1247. e9.
62. Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial[J]. JAMA Netw Open, 2021, 4(1): e2033457.
63. Deaton AM, Dubey A, Ward LD, et al. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity[J]. Nat Commun, 2022, 13(1): 4319.
64. Akbari P, Sosina OA, Bovijn J, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes[J]. Nat Commun, 2022, 13(1): 4844.

Previous Article
慢性阻塞性肺病合并認知障礙的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

慢性阻塞性肺疾病合并肌少癥性肥胖的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content